Corvus Pharmaceuticals's total assets for Q2 2025 were $89.46M, an increase of 50.51% from the previous quarter. CRVS total liabilities were $9.23M for the fiscal quarter, a -8.70% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.